Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus
dexamethasone and ondansetron is more effective in the prevention of vomiting than
dexamethasone and ondansetron alone following the administration of moderately emetogenic
chemotherapy.